Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

被引:681
作者
Fiolet, Thibault [1 ]
Kherabi, Yousra [2 ,3 ]
MacDonald, Conor-James [1 ]
Ghosn, Jade [2 ,3 ]
Peiffer-Smadja, Nathan [2 ,3 ,4 ]
机构
[1] Paris Saclay Univ, UVSQ, INSERM, Gustave Roussy,Exposome & Hered Team,CESP UMR1018, Villejuif, France
[2] Univ Paris, IAME, INSERM, Paris, France
[3] Bichat Claude Bernard Hosp, AP HP, Infect & Trop Dis Dept, Paris, France
[4] Imperial Coll, Natl Inst Hlth Res Hlth Protect Res Unit Healthca, London, England
关键词
Coronavirus; COVID-19; Delta; Efficacy; Review; SARS-CoV-2; Seroneutralization; Vaccines; Variants; VACCINATION STATUS; HOSPITALIZATIONS; ADULTS; NEUTRALIZATION; PREDOMINANCE; INFECTION; BINDING; SAFETY; STATES;
D O I
10.1016/j.cmi.2021.10.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Vaccines are critical cost-effective tools to control the coronavirus disease 2019 (COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may threaten the global impact of mass vaccination campaigns. Aims: The objective of this study was to provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for 19 COVID-19 vaccines. Sources: References for this review were identified through searches of PubMed, Google Scholar, BioRxiv, MedRxiv, regulatory drug agencies and pharmaceutical companies' websites up to 22nd September 2021. Content: Overall, all COVID-19 vaccines had a high efficacy against the original strain and the variants of concern, and were well tolerated. BNT162b2, mRNA-1273 and Sputnik V after two doses had the highest efficacy (>90%) in preventing symptomatic cases in phase III trials. mRNA vaccines, AZD1222, and CoronaVac were effective in preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta variants. Regarding observational real-life data, full immunization with mRNA vaccines and AZD1222 seems to effectively prevent SARS-CoV-2 infection against the original strain and Alpha and Beta variants but with reduced effectiveness against the Delta strain. A decline in infection protection was observed at 6 months for BNT162b2 and AZD1222. Serious adverse event rates were rare for mRNA vaccinesdanaphylaxis 2.5-4.7 cases per million doses, myocarditis 3.5 cases per million dosesdand were similarly rare for all other vaccines. Prices for the different vaccines varied from $2.15 to $29.75 per dose. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:202 / 221
页数:20
相关论文
共 190 条
[1]  
Abdala Vacuna, 2021, 100 EF ANT ENF SEV M
[2]   Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines [J].
Abu-Hammad, Osama ;
Alduraidi, Hamza ;
Abu-Hammad, Shaden ;
Alnazzawi, Ahmed ;
Babkair, Hamzah ;
Abu-Hammad, Abdalla ;
Nourwali, Ibrahim ;
Qasem, Farah ;
Dar-Odeh, Najla .
VACCINES, 2021, 9 (06)
[3]   Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Butt, Adeel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189
[4]  
Acevedo ML., 2021, INFECTIVITY IMMUNE E, DOI DOI 10.1101/2021.06.28.21259673
[5]   Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial [J].
Al Kaabi, Nawal ;
Zhang, Yuntao ;
Xia, Shengli ;
Yang, Yunkai ;
Al Qahtani, Manaf M. ;
Abdulrazzaq, Najiba ;
Al Nusair, Majed ;
Hassany, Mohamed ;
Jawad, Jaleela S. ;
Abdalla, Jehad ;
Hussein, Salah Eldin ;
Al Mazrouei, Shamma K. ;
Al Karam, Maysoon ;
Li, Xinguo ;
Yang, Xuqin ;
Wang, Wei ;
Lai, Bonan ;
Chen, Wei ;
Huang, Shihe ;
Wang, Qian ;
Yang, Tian ;
Liu, Yang ;
Ma, Rui ;
Hussain, Zaidoon M. ;
Khan, Tehmina ;
Saifuddin Fasihuddin, Mohammed ;
You, Wangyang ;
Xie, Zhiqiang ;
Zhao, Yuxiu ;
Jiang, Zhiwei ;
Zhao, Guoqing ;
Zhang, Yanbo ;
Mahmoud, Sally ;
ElTantawy, Islam ;
Xiao, Peng ;
Koshy, Ashish ;
Zaher, Walid Abbas ;
Wang, Hui ;
Duan, Kai ;
Pan, An ;
Yang, Xiaoming .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01) :35-45
[6]   Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis [J].
Allotey, John ;
Stallings, Elena ;
Bonet, Mercedes ;
Yap, Magnus ;
Chatterjee, Shaunak ;
Kew, Tania ;
Debenham, Luke ;
Llavall, Anna Clave ;
Dixit, Anushka ;
Zhou, Dengyi ;
Balaji, Rishab ;
Lee, Siang Ing ;
Qiu, Xiu ;
Yuan, Mingyang ;
Coomar, Dyuti ;
van Wely, Madelon ;
van Leeuwen, Elizabeth ;
Kostova, Elena ;
Kunst, Heinke ;
Khalil, Asma ;
Tiberi, Simon ;
Brizuela, Vanessa ;
Broutet, Nathalie ;
Kara, Edna ;
Kim, Caron Rahn ;
Thorson, Anna ;
Oladapo, Olufemi T. ;
Mofenson, Lynne ;
Zamora, Javier ;
Thangaratinam, Shakila .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
[7]   Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study [J].
Almufty, Hind B. ;
Mohammed, Shinah A. ;
Abdullah, Arshad M. ;
Merza, Muayad A. .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (05)
[8]  
Andrejko KL, CLIN INFECT DIS, V2021
[9]   Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers [J].
Angel, Yoel ;
Spitzer, Avishay ;
Henig, Oryan ;
Saiag, Esther ;
Sprecher, Eli ;
Padova, Hagit ;
Ben-Ami, Ronen .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (24) :2457-2465
[10]   SARS-CoV-2 Antibody Response in Persons with Past Natural Infection [J].
Anichini, Gabriele ;
Terrosi, Chiara ;
Gandolfo, Claudia ;
Gori Savellini, Gianni ;
Fabrizi, Simonetta ;
Miceli, Giovanni B. ;
Cusi, M. Grazia .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01) :90-92